Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK2 | P53671 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.45 |
| ▸ | STS | P08842 | 2/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29772899 | 1.00 | LIMK2 (0.48) | LIMK2USP30TGFBR1GPR119STS | |
| SCHEMBL30936639 | 0.95 | LIMK2 (0.51) | LIMK2TGFBR1GPR119STSMMP13 | |
| SCHEMBL29772863 | 0.88 | NPY2R (0.52) | LIMK2USP30GPR119NPY2R | |
| SCHEMBL24628372 | 0.88 | NPY2R (0.52) | LIMK2USP30GPR119NPY2R | |
| SCHEMBL24628795 | 0.86 | MCOLN2 (0.42) | NPY2R | |
| SCHEMBL29772864 | 0.86 | MCOLN2 (0.42) | NPY2R | |
| SCHEMBL23355023 | 0.81 | LIMK2 (0.53) | LIMK2TGFBR1GPR119STSMMP13 | |
| SCHEMBL24628788 | 0.81 | MCOLN2 (0.46) | — | |
| SCHEMBL30936612 | 0.79 | HTR2A (0.50) | — | |
| SCHEMBL23355043 | 0.78 | MCOLN3 (0.50) | LIMK2TGFBR1GPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022150461-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |